Neuroblastomas Clinical Studies

Some of the many Hematology/Oncology research opportunities available related to neuroblastomas are listed below. Select a study to review a brief description and requirements. Parents or guardians of children who might be eligible are encouraged to inquire about enrollment. Contact information is provided at the end of each study.

Please note that Pilot and Phase I studies are the most experimental and should be considered only after other treatments or trials have been attempted without success.

Thank you for exploring these opportunities and helping us to find cures and prevent childhood disease.

Clinical Studies

Researchers

Pediatric Tumors and Specimen Study

A Children’s Oncology Group Protocol for Collecting and Banking Pediatric Specimens Including Rare Pediatric Tumors

Read more

Solid Tumor and Lymphoma Treatment with PF-02341066 – Phases I and II

PF-02341066, an Oral Small Molecule Inhibitor of Anaplastic Lymphoma Kinase (ALK) and c-MET, in Children with Relapsed/Refractory Solid Tumors and Anaplastic Large Cell Lymphoma

Read more

Solid Tumor Treatment with MK-1775 – Phase I/II

MK-1775 in Combination with Oral Irinotecan in Children, Adolescents, and Young Adults with Relapsed or Refractory Solid Tumors

Read more

Solid Tumor Treatment with MLN4924, Temozolomide & Irinotecan

Study of Pevonedistat (MLN4924), a NEDD8-Activating Enzyme Inhibitor, in Combination with Temozolomide and Irinotecan in Pediatric Patients with Recurrent or Refractory Solid Tumors

Read more

Solid Tumor Treatment With nab-Rapamycin, Temozolomide & Irinotecan – Phase I

Study of ABI-009 (nab-Rapamycin) in Pediatric Patients with Recurrent or Refractory Solid Tumors, Including CNS Tumors, as a Single Agent and in Combination with Temozolomide and Irinotecan

Read more

Solid Tumor Treatment with Nivolumab with and without Ipilimumab – Phase I/II

Study of Nivolumab in Children, Adolescents, and Young Adults With Recurrent or Refractory Solid Tumors as a Single Agent and in Combination With Ipilimumab

Read more

Solid Tumor Treatment with Ramucirumab – Phase I

A Study of Ramucirumab, a Human Monoclonal Antibody Against the Vascular Endothelial Growth Factor-2 Receptor in Children with Refractory Solid Tumors, Including CNS Tumors

Read more

Solid Tumor Treatment with Selinexor – Phase I

Study of Selinexor (KPT-330), a Selective XPO1 Inhibitor, in Recurrent and Refractory Pediatric Solid Tumors Including CNS Tumors

Read more